Alnylam Expected to Reach Breakeven by 2025 and Turn Profitable in 2026 Per Analyst Estimates
• Alnylam Pharmaceuticals is expected to reach breakeven in 2025 and make a profit of $292 million in 2026, according to analysts • The company needs an average annual growth rate of 58% to meet the 2025 breakeven target • Alnylam is investing heavily currently, leading to negative equity and losses, but this is common for biotech companies • Investors should look at management, valuation, and other stock prospects to fully evaluate Alnylam • The analysis doesn't account for latest news or qualitative factors, so more research is needed from investors